New hope to tame dangerous CAR-T therapy side effects
NCT ID NCT04975555
Summary
This study is testing whether a drug called siltuximab can help control two serious side effects that sometimes occur after CAR-T cell therapy for blood cancers. CAR-T therapy can cause dangerous immune overreactions called cytokine release syndrome (CRS) and neurological problems (ICANS). The trial will enroll 30 patients to see if siltuximab given at the first sign of these side effects can resolve them safely and effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.